Overall, BR demonstrated better long-term disease control than R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.
No takes yet. Share an insight, caveat, or question.
Flinn et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: